selected publications academic article Zisook, S., Moutier, C. Y., Rush, A. J., Johnson, G. R., Tal, I., Chen, P. J., ... Mohamed, S. (2023). Effect of next-step antidepressant treatment on suicidal ideation: findings from the VAST-D trial. Psychological Medicine. 1-12. Zisook, S., Planeta, B., Hicks, P. B., Chen, P., Davis, L. L., Villarreal, G., ... Mohamed, S. (2022). Childhood adversity and adulthood major depressive disorder. 76, 36-44. Zisook, S., Johnson, G. R., Hicks, P., Chen, P., Beresford, T., Michalets, J. P., ... Mohamed, S. (2021). Continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment-resistant major depressive disorder: A VAST-D report. 38(2), 185-195. Mohamed, S., Johnson, G. R., Sevilimedu, V., Rao, S. D., Hicks, P. B., Chen, P., ... CSP#576 VAST-D Investigators. (2020). Impact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial. Journal of Clinical Psychiatry. 81(4), 19m13038. Zisook, S., Johnson, G. R., Tal, I., Hicks, P., Chen, P., Davis, L., ... Mohamed, S. (2019). General Predictors and Moderators of Depression Remission: A VAST-D Report. American Journal of Psychiatry. 176(5), 348-357. Hicks, P. B., Sevilimedu, V., Johnson, G. R., Tal, I., Chen, P., Davis, L. L., ... Zisook, S. (2019). Predictability of Nonremitting Depression After First 2Weeks of Antidepressant Treatment: A VAST-D Trial Report. Psychiatric Research and Clinical Practice. 1(2), 58-67. Mohamed, S., Johnson, G. R., Chen, P., Hicks, P. B., Davis, L. L., Yoon, J., ... Little, J. T. (2017). Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. Journal of the American Medical Association (JAMA). 318(2), 132-145. Krystal, J. H., Pietrzak, R. H., Rosenheck, R. A., Cramer, J. A., Vessicchio, J., Jones, K. M., ... Veterans Affairs Cooperative Study #504 Group. (2016). Sleep disturbance in chronic military-related PTSD: clinical impact and response to adjunctive risperidone in the Veterans Affairs cooperative study #504. Journal of Clinical Psychiatry. 77(4), 483-491. Zisook, S., Tal, I., Weingart, K., Hicks, P., Davis, L. L., Chen, P., ... Mohamed, S. (2016). Characteristics of U.S. Veteran Patients with Major Depressive Disorder who require "next-step" treatments: A VAST-D report. JOURNAL OF AFFECTIVE DISORDERS. 206, 232-240. Mohamed, S., Johnson, G. R., Vertrees, J. E., Guarino, P. D., Weingart, K., Young, I. T., ... Zisook, S. (2015). The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations. Psychiatry Research. 229(3), 760-770. Leatherman, S. M., Liang, M. H., Krystal, J. H., Lew, R. A., Valley, D., Thwin, S. S., Rosenheck, R. A., & CSP 555 Investigators. (2014). Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia. 202(1), 13-17. Copeland, L. A., Pugh, M. J., Hicks, P. B., & Noel, P. H. (2012). Use of obesity-related care by psychiatric patients. 63(3), 230-236. Young, K. A., Bonkale, W. L., Holcomb, L. A., Hicks, P. B., & German, D. C. (2008). Major depression, 5HTTLPR genotype, suicide and antidepressant influences on thalamic volume. British Journal of Psychiatry. 192(4), 285-289. Young, K. A., Holcomb, L. A., Bonkale, W. L., Hicks, P. B., Yazdani, U., & German, D. C. (2007). 5HTTLPR polymorphism and enlargement of the pulvinar: unlocking the backdoor to the limbic system. Biological Psychiatry. 61(6), 813-818. Schubert, M. H., Young, K. A., & Hicks, P. B. (2006). Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biological Psychiatry. 60(6), 530-533. Browning, J. L., Patel, T., Brandt, P. C., Young, K. A., Holcomb, L. A., & Hicks, P. B. (2005). Clozapine and the mitogen-activated protein kinase signal transduction pathway: implications for antipsychotic actions. Biological Psychiatry. 57(6), 617-623. Young, K. A., Holcomb, L. A., Yazdani, U., Hicks, P. B., & German, D. C. (2004). Elevated neuron number in the limbic thalamus in major depression. American Journal of Psychiatry. 161(7), 1270-1277. Wadenberg, M. G., Browning, J. L., Young, K. A., & Hicks, P. B. (2001). Antagonism at 5-HT(2A) receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats. Pharmacology, Biochemistry and Behavior. 68(3), 363-370. Young, K. A., Smith, M., Rawls, T., Elliott, D. B., Russell, I. S., & Hicks, P. B. (2001). N100 evoked potential latency variation and startle in schizophrenia. NeuroReport. 12(4), 767-773. Young, K. A., Manaye, K. F., Liang, C., Hicks, P. B., & German, D. C. (2000). Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia. Biological Psychiatry. 47(11), 944-953. Barwick, V. S., Jones, D. H., Richter, J. T., Hicks, P. B., & Young, K. A. (2000). Subthalamic nucleus microinjections of 5-HT2 receptor antagonists suppress stereotypy in rats. NeuroReport. 11(2), 267-270. Wadenberg, M. L., Young, K. A., Richter, J. T., & Hicks, P. B. (1999). Effects of local application of 5-hydroxytryptamine into the dorsal or median raphe nuclei on haloperidol-induced catalepsy in the rat. Neuropharmacology. 38(1), 151-156. Wadenberg, M. L., & Hicks, P. B. (1999). The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics?. Neuroscience and Biobehavioral Reviews. 23(6), 851-862. Wadenberg, M. L., Hicks, P. B., Richter, J. T., & Young, K. A. (1998). Enhancement of antipsychoticlike properties of raclopride in rats using the selective serotonin2A receptor antagonist MDL 100,907. Biological Psychiatry. 44(6), 508-515. Jeste, D. V., Klausner, M., Brecher, M., Clyde, C., & Jones, R. (1997). A clinical evaluation of risperidone in the treatment of schizophrenia: a 10-week, open-label, multicenter trial. ARCS Study Group. Assessment of Risperdal in a Clinical Setting. Psychopharmacology. 131(3), 239-247. Wadenberg, M. L., Young, K. A., Trompler, R. A., Zavodny, R. A., Richter, T. J., & Hicks, P. B. (1997). A novel computer-controlled conditioned avoidance apparatus for rats. Journal of Pharmacological and Toxicological Methods. 38(4), 211-215. Young, K. A., Hicks, P. B., Randall, P. K., & Wilcox, R. E. (1994). Behavioral and frontal cortical metabolic effects of apomorphine and muscimol microinjections into the mediodorsal thalamic nucleus. JOURNAL OF NEURAL TRANSMISSION. 98(2), 119-132. Hicks, P., Young, K., & Zavodny, R. (1993). Further evidence for a 5-HT-1C modulation of apomorphine-induced locomotor activity. 9(2-3), 238-238. Young, K. A., Zavodny, R., & Hicks, P. B. (1993). Effects of serotonergic agents on apomorphine-induced locomotor activity. 110(1-2), 97-102. Young, K. A., Zavodny, R., & Hicks, P. B. (1991). Subchronic buspirone, mesulergine, and ICS 205-930 lack effects on D1 and D2 dopamine binding in the rat striatum during chronic haloperidol treatment. 86(3), 223-228. Hicks, P. B. (1990). The effect of serotonergic agents on haloperidol-induced catalepsy. LIFE SCIENCES. 47(18), 1609-1615. Hicks, P. B., Vinogradov, S., Riney, S. J., Su, K., & Csernansky, J. G. (1989). A preliminary dose-ranging trial of proglumide for the treatment of refractory schizophrenics. Journal of Clinical Psychopharmacology. 9(3), 209-212. Hicks, P., Rolsten, C., Brizzee, D., & Samorajski, T. (1983). Age-related changes in rat brain capillaries. Neurobiology of Aging. 4(1), 69-75. Misra, C. H., Hicks, P., Rolsten, C., Smith, R. C., & Schoolar, J. C. (1982). Regional uptake of [35S]-cysteine in rat brain after arterial injection. Research communications in chemical pathology and pharmacology. 37(1), 155-158. Hicks, P., Rolsten, C., Taylor, D., & Samorajski, T. (1982). Plasma choline and blood cholinesterases in aged rats. Gerontology: international journal of experimental, clinical, behavioral, regenerative and technical gerontology. 28(2), 104-107. Rolsten, C., Hicks, P., Samorajski, T., & Schoolar, J. (1982). Decreased response latency time of aged C57BL/6J male mice to benzodiazepines. 5(4), 146-147. Strong, R., Hicks, P., Hsu, L., Bartus, R. T., & Enna, S. J. (1980). Age-related alterations in the rodent brain cholinergic system and behavior. Neurobiology of Aging. 1(1), 59-63. Hicks, P., Strong, R., Schoolar, J. C., & Samorajski, T. (1980). Aging alters amphetamine-induced stereotyped gnawing and neostriatal elimination of amphetamine in mice. LIFE SCIENCES. 27(9), 715-722. Smith, R. C., Strong, J. R., Hicks, P. B., & Samorajski, T. (1979). Behavioral evidence for supersensitivity after chronic bromocriptine administration. Psychopharmacology. 60(3), 241-246. STRONG, R., SMITH, R., & HICKS, P. (1978). INCREASED BEHAVIORAL-EFFECTS OF DOPAMINE AGONISTS IN AGED RODENTS. Pharmacologist -Washington-. 20(3), 172-172. Hicks, P. B., Sevilimedu, V., Johnson, G. R., Tal, I. R., Chen, P., Davis, L. L., ... Mohamed, S. Factors Affecting Antidepressant Response Trajectories: A Veterans Affairs Augmentation and Switching Treatments for Improving Depression Outcomes Trial Report. Psychiatric Research and Clinical Practice. chapter Smith, C. M., Hicks, P. B., Lindefjeld, J. K., Taylor, B. M., Fisher, D. R., Faragon, J. J., ... Cozza, K. L. (2022). Antiretrovirals and Psychotropics: Drug Interactions and Complications. HIV Psychiatry. (pp. 415-476). Springer Nature. conference paper Young, K. A., Bonkale, W., Sachsenmaier, S., & Hicks, P. (2009). VA/VL THALAMIC CELL NUMBER IN SCHIZOPHRENIA AND MOOD DISORDERS. Schizophrenia Bulletin. 226-227. Young, K. A., Holcomb, L. A., Bonkale, W. L., & Hicks, P. B. (2007). Normal oligodendrocyte cell numbers in anterior thalamus in schizophrenia Normal oligodendrocyte cell numbers in anterior thalamus in schizophrenia. Schizophrenia Bulletin. 274-274. Schubert, M. H., Young, K. A., Justice, S. B., Durgam, S. K., Schmitz, W. M., House, M. D., & Hicks, P. B. (2005). Cognitive improvement in schizophrenia and schizoaffective disorder by augmentation of risperidone with galantamine. Schizophrenia Bulletin. 503-503. Browning, J. L., Young, K. A., & Hicks, P. B. (2005). The MEK/ERK map kinase pathway in antipsychotic actions. Schizophrenia Bulletin. 296-296. German, D., Yazdani, U., Hicks, P., & Young, K. (2004). Increased number of neurons in the limbic thalamus in major depressive disorder. Biological Psychiatry. 84S-84S. Hicks, P. B., Browning, J. L., Schubert, M. H., & Young, K. A. (2003). 5-HT2A antagonism does not affect catalepsy in rats. Schizophrenia Research. 356-357. Young, K. A., Skol, A. S., Tsuang, D. W., Faraone, S. V., Bingham, S., Prabhudesai, S., ... Tsuang, M. T. (2003). Association of NOTCH4 with schizophrenia in VA Coop Study # 366. Schizophrenia Research. 92-92. Browning, J. L., Young, K. A., Holcomb, L. A., Jones, D. H., & Hicks, P. B. (2003). The role of the MAP kinase ERK pathway in the antipsychotic actions of clozapine. Schizophrenia Research. 309-309. Holcomb, L. A., Hicks, P. B., Metz, D. S., Stepp, S., & Young, K. A. (2001). Anterior thalamic volume in schizophrenia and mood disorders. Schizophrenia Research. 61-61. Young, K. A., Russell, I. S., & Hicks, P. B. (2001). Changes in evoked potential latency variation over time are associated with changes in EP and startle gating in schizophrenic patients. Schizophrenia Research. 126-126. Browning, J. L., Patel, T., Brandt, P. C., Young, K. A., & Hicks, P. B. (2001). Is the mechanism of action of antipsychotic agents mediated through the MAP kinase signal transduction system?. Schizophrenia Research. 87-88. Holcomb, L. A., Manaye, E. F., German, D. C., Hicks, P. B., & Young, K. A. (1999). GFAP and Rab3a immunoreactivity in the thalamus of schizophrenics. Schizophrenia Research. 81-81. Young, K. A., Smith, M., Clark, W., Hicks, P. B., & Russell, I. S. (1999). Incidence of startle prepulse inhibition deficits in schizophrenics. Schizophrenia Research. 188-188. Hicks, P. B., Browning, J., Barwick, S., Jones, D., Wadenberg, M. L., Richter, J. T., & Young, K. A. (1999). M100,907 acts at both the nucleus accumbens and the prefrontal cortex to mediate the enhancement of the suppression of conditioned avoidance response by haloperidol. Schizophrenia Research. 115-115. Barwick, V. S., Manaye, K. F., Brandt, A., German, D. C., Hicks, P. B., & Young, K. A. (1999). Stereological estimate of total thalamic neuron number in schizophrenics. Schizophrenia Research. 79-79. Wadenberg, M., Hicks, P. B., Young, K. A., & Richter, J. T. (1997). Further evidence for a role of the 5-HT2A receptor in the mediation of antipsychotic activity. Schizophrenia Research. 83-83. YOUNG, K. A., BRADY, M. D., & HICKS, P. B. (1995). PSYCHOPHYSIOLOGICAL EVIDENCE FOR NEUROLEPTIC-INDUCED DEPOLARIZATION BLOCK IN SCHIZOPHRENICS. Schizophrenia Research. 170-171.
principal investigator on IPA for Jeffrey Browning awarded by Central Texas Veterans Health Care System - (Waco, Texas, United States) 2017 - 2018
education and training M.D. in Medicine, Baylor College of Medicine - (Houston, Texas, United States) 1983 Ph.D. in Pharmacology, Baylor College of Medicine - (Houston, Texas, United States) 1983 Stanford Medicine - (Stanford, California, United States) , Medical Residency 1987 Baylor College of Medicine - (Houston, Texas, United States) , Medical Residency 1984